Liso-cel
Liso-cel 是目前在国外临床研究中出现的一款新药或疗法，主要研究方向为Lymphoma。下面汇总了它当前在全球正在招募患者的研究，以及中国患者可以走的申请途径。
14 项
全球在招研究
1 项
已进入 III/IV 期
7 个
开展国家和地区
暂未检索到
中国境内设点
药品与企业信息
研发企业
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Marcela V. Maus, M.D.,Ph.D.
- M.D. Anderson Cancer Center
- Fred Hutchinson Cancer Center
- Lyell Immunopharma, Inc.
- SWOG Cancer Research Network
- Aseel Alsouqi
- Weill Medical College of Cornell University
汇总自相关试验登记的主要申办方；研究机构申办时会显示相应机构名称。
生产企业
公开药品批准资料或正式说明书暂未提供明确的生产企业信息。
研发企业与生产企业可能不是同一家。研究阶段药品可能尚未公布生产企业；生产企业仅取自美国上市原研药说明书所列企业（不含仿制药），不作推测；仅在其他国家上市的药品暂无法显示。
主要开展国家和地区
美国、法国、德国、澳大利亚、加拿大、日本、瑞士
正在招募患者的 Liso-cel 研究
Emapalumab Prevention of CAR-T Cell Associated Toxicities
II 期招募中美国NCT06550141A Study of the Efficacy and Safety of Lisocabtagene Maraleucel (Liso-cel) as First-Line Therapy in Adults With Transplant-Ineligible Primary Central Nervous System Lymphoma
II 期招募中美国法国德国NCT07015242Phase 2 Trial of Lisocabtagene Maraleucel for Minimal Residual Disease in Patients With Large B-cell Lymphoma
II 期招募中美国NCT07316010Nemtabrutinib and Lisocabtagene Maraleucel for the Treatment of Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma
II 期招募中美国NCT07194980A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy
III 期招募中美国澳大利亚加拿大NCT07188558A Study of Patients With Relapsed/Refractory Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
不适用招募中美国NCT06788639Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma
II 期招募中美国NCT05633615Zanubrutinib and Lisocabtagene Maraleucel for the Treatment of Richter's Syndrome
II 期招募中美国NCT05873712A Study of Patients With Relapsed/Refractory Mantle Cell Lymphoma Treated With Lisocabtagene Maraleucel in the Post-Marketing Setting
不适用招募中美国NCT06788652Low-Dose TBI Plus CAR T-Cell Therapy for Relapsed/Refractory DLBCL and Multiple Myeloma
I 期招募中美国NCT07725406A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting
不适用招募中美国NCT06794268GLORY: Glofit-GemOx With Liso-Cel For Lymphoma
II 期招募中美国NCT07711483NT-I7 (Efineptakin Alfa), a Long-acting Human IL-7, Post-Axicabtagene Ciloleucel or Post-Lisocabtagene Maraleucel in Subjects With Relapsed/Refractory Large B-cell Lymphoma
I 期招募中美国NCT07052305Transgene Assay Testing Service of Tumor Samples From Patients Who Received a Bristol-Myers Squibb Manufactured Gene Modified Cell Therapy and Have a Qualifying Second Primary Malignancy
不适用招募中美国德国日本瑞士NCT06357754
中国患者怎么争取用上这款药
目前境内暂未检索到设点，下面几条途径是更现实的选择，每条都有详细的中文做法。
查看完整申请指南同类方向的其他在研新药
本页信息整理自 ClinicalTrials.gov 公开登记数据，仅供参考，不构成医疗建议；是否适合使用该药物，请以专业医生和研究团队的意见为准。